Pharmacom Dro P100

Drostanolone was first described in 1959; developed by Syntex and entered the market more than a decade later, in 1970, under the trade name Masteron.

Drostanolone is an injectable anabolic steroid, a derivative of dihydrotestosterone (DHT). It is described in medical literature as a strong anabolic with anti-estrogenic traits. The FDA approved drostanolone for the treatment of inoperable breast cancer in climacteric women, as was the case in many other parts of the worlds.

Biologically, Masteron acts like DHT, as it is a derivative of the latter. Without question, the effects of Masteron will be displayed in the most efficient way during a cutting cycle. However, for the effects to be truly appreciated the individual will need to be extremely lean. Drostanolone does not cause water retention and has a moderate diuretic effect similarly to stanozolol; this allows improving muscles density, relief and definition. Drostanolone allows achievement of the best muscle condition; it is possible thanks largely to the lipolytic effect of the compound. As practice shows, a drostanolone cycle can reduce body fat by 5-7%. Drostanolone is recommended for track and field athletes and bodybuilders who want to stay within their particular weight class.